DE69626855D1 - Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften - Google Patents

Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften

Info

Publication number
DE69626855D1
DE69626855D1 DE69626855T DE69626855T DE69626855D1 DE 69626855 D1 DE69626855 D1 DE 69626855D1 DE 69626855 T DE69626855 T DE 69626855T DE 69626855 T DE69626855 T DE 69626855T DE 69626855 D1 DE69626855 D1 DE 69626855D1
Authority
DE
Germany
Prior art keywords
purine derivatives
antipoliferative
rnh
cyclin
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69626855T
Other languages
English (en)
Other versions
DE69626855T2 (de
Inventor
Laurent Meijer
Emile Bisagni
Michel Legraverend
Miroslav Strnad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST BOTAN EXPERIMENTALE PRAG
Centre National de la Recherche Scientifique CNRS
Original Assignee
INST BOTAN EXPERIMENTALE PRAG
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INST BOTAN EXPERIMENTALE PRAG, Centre National de la Recherche Scientifique CNRS filed Critical INST BOTAN EXPERIMENTALE PRAG
Publication of DE69626855D1 publication Critical patent/DE69626855D1/de
Application granted granted Critical
Publication of DE69626855T2 publication Critical patent/DE69626855T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69626855T 1995-12-01 1996-11-29 Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften Expired - Lifetime DE69626855T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514237A FR2741881B1 (fr) 1995-12-01 1995-12-01 Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
PCT/FR1996/001905 WO1997020842A1 (fr) 1995-12-01 1996-11-29 Nouveaux derives de purine possedant notamment des proprietes anti-proliferatives et leurs applications biologiques

Publications (2)

Publication Number Publication Date
DE69626855D1 true DE69626855D1 (de) 2003-04-24
DE69626855T2 DE69626855T2 (de) 2003-12-24

Family

ID=9485066

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69638337T Expired - Lifetime DE69638337D1 (de) 1995-12-01 1996-11-29 Purin-Derivat zur Anwendung in der Behandlung einer proliferativen Erkrankung
DE69626855T Expired - Lifetime DE69626855T2 (de) 1995-12-01 1996-11-29 Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69638337T Expired - Lifetime DE69638337D1 (de) 1995-12-01 1996-11-29 Purin-Derivat zur Anwendung in der Behandlung einer proliferativen Erkrankung

Country Status (11)

Country Link
US (6) US6316456B1 (de)
EP (2) EP0874847B1 (de)
JP (1) JP4340796B2 (de)
AT (2) ATE234838T1 (de)
CA (1) CA2238843C (de)
DE (2) DE69638337D1 (de)
DK (2) DK1308447T3 (de)
ES (2) ES2195027T3 (de)
FR (1) FR2741881B1 (de)
PT (2) PT1308447E (de)
WO (1) WO1997020842A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT874846E (pt) 1995-11-01 2003-08-29 Novartis Ag Derivados de purina e processos para a sua preparacao
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6794390B2 (en) * 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
CA2287531A1 (en) 1997-03-03 1998-09-11 Board Of Regents, The University Of Texas System Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
CA2301830A1 (en) * 1997-09-05 1999-03-18 Cropdesign N.V. Method and means for modulating plant cell cycle proteins and their use in controlling plant cell growth
US7265267B1 (en) 1997-09-16 2007-09-04 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
WO1999014331A2 (en) * 1997-09-16 1999-03-25 Cropdesign Nv Cyclin-dependent kinase inhibitors and uses thereof
US6710227B1 (en) 1998-09-16 2004-03-23 Cropdesign N.V. Cyclin-dependent kinase inhibitors and uses thereof
EP0911634A1 (de) * 1997-10-24 1999-04-28 Het Nederlands Kanker Instituut Pharmazeutische Verwendungen von Regulatoren der CDK-2
EP1025232A1 (de) * 1997-10-24 2000-08-09 CropDesign N.V. Mitogenes cyclin und dessen verwendung
PT1056744E (pt) * 1998-02-26 2004-03-31 Aventis Pharma Inc 2-¬trans-(4-aminociclo-hexil)amino|purinas 6,9-dissubstituidas
DE69918062T2 (de) * 1998-02-26 2005-06-02 Aventis Pharmaceuticals Inc. 6,9-disubstituierte 2-(trans-(4-aminocyclohexyl)amino)purine
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6642231B2 (en) * 1998-02-26 2003-11-04 Aventis Pharmaceuticals Inc. 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
AU753015B2 (en) * 1998-03-04 2002-10-03 Cyclacel Limited Cyclin dependent kinase inhibitor
US6703395B2 (en) * 1998-03-04 2004-03-09 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
GB9806739D0 (en) * 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
US6664439B1 (en) 1998-04-28 2003-12-16 The Procter & Gamble Company Absorbent articles with distribution materials positioned underneath storage material
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
AU1559400A (en) * 1998-12-04 2000-06-26 Cropdesign N.V. Method to identify regulators of cdk activity
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
RU2001124352A (ru) * 1999-02-01 2004-02-20 Си Ви Терапьютикс, Инк. (Us) Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа
AU2004200192B2 (en) * 1999-02-01 2006-11-16 Gilead Palo Alto, Inc. Purine inhibitors of cyclin dependent kinase 2 and 1k-Aa
EP1026251A3 (de) * 1999-02-03 2000-09-06 Pfizer Products Inc. Transgene Tiere welche das menschliche p25 Gen exprimieren
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
CA2396276A1 (en) * 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
CN1433417A (zh) * 2000-01-27 2003-07-30 沃尼尔·朗伯公司 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US20040254094A1 (en) * 2000-10-11 2004-12-16 The Trustees Of University Of Pennsylvania And Board Of Regents Suppression of cyclin kinase activity for prevention and treatment of infections
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
US6667311B2 (en) 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
WO2003031406A2 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20050222054A1 (en) * 2002-03-27 2005-10-06 Cyclacel Limited Combination comprising a CDK inhibitor and doxorubicin
AU2003279690A1 (en) * 2002-06-27 2004-01-19 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
AU2003272503A1 (en) * 2002-09-17 2004-04-08 University Of Utah Research Foundation Methods and compositions related to inhibiting nuclear envelope breakdown
GB0225873D0 (en) * 2002-11-06 2002-12-11 Cyclacel Ltd Combination
JP4764165B2 (ja) * 2002-11-06 2011-08-31 サイクラセル リミテッド ドセタキセル及びｃｄｋ阻害剤を含む組合せ
CA2502969A1 (en) * 2002-11-06 2004-05-21 Cyclacel Limited Combination comprising a cdk inhibitor and cisplatin
ATE409484T1 (de) * 2002-12-17 2008-10-15 Centre Nat Rech Scient Verwendung von purinderivaten zur induktion der differenzierung überzähliger haarzellen und deiter-zellen im entwickelnden corti-organ zur behandlung von taubheit
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
GB0307640D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers
GB0315259D0 (en) * 2003-06-30 2003-08-06 Cyclacel Ltd Use
WO2005044275A1 (en) * 2003-11-06 2005-05-19 Cyclacel Limited Use
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
MX2007002169A (es) 2004-08-27 2007-08-14 Cyclacel Ltd Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.
CN101899049A (zh) 2004-10-13 2010-12-01 霍夫曼-拉罗奇有限公司 二取代吡唑并苯并二氮杂*类
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
KR20110010813A (ko) * 2005-10-14 2011-02-07 에프. 호프만-라 로슈 아게 5-(2-클로로페닐)-1,2-디히드로-7-플루오로-8-메톡시-3-메틸-피라졸로[3,4-ｂ][1,4] 벤조디아제핀의 투여 섭생
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
FR2899107B1 (fr) * 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008051502A1 (en) 2006-10-19 2008-05-02 Genzyme Corporation Purine derivatives for the treatment of cystic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
KR101564233B1 (ko) * 2007-03-28 2015-10-29 뉴로서치 에이/에스 푸리닐 유도체 및 칼륨 채널 조절제로서의 이의 용도
WO2008116912A2 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
CZ300774B6 (cs) * 2007-10-05 2009-08-05 Univerzita Palackého Substituované 6-(alkylbenzylamino)purinové deriváty pro použití jako antagonisté cytokininových receptoru a prípravky obsahující tyto slouceniny
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
JP2011207764A (ja) * 2008-07-29 2011-10-20 Univ Of Tokyo Ｃｄｋ阻害剤によるｃ型肝炎ウイルスの複製抑制
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
CZ302623B6 (cs) * 2009-04-22 2011-08-03 Univerzita Palackého Oxalátokomplexy platiny s deriváty N6-benzyladeninu, zpusob jejich prípravy a použití techto komplexu jako léciv v protinádorové terapii
FR2945747A1 (fr) 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
UY33883A (es) 2011-01-31 2012-08-31 Novartis Ag Novedosos derivados heterocíclicos
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP2561867A1 (de) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9-Hemmer zur Behandlung eines Mittellinienkarzinoms
EP2562265A1 (de) 2011-08-22 2013-02-27 Lead Discovery Center GmbH Empfindlichkeit auf selektive CDK9-Inhibitoren
BR112014009890A2 (pt) 2011-10-28 2020-10-27 Novartis Ag derivados de purina e seu uso no tratamento de doença
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
EP2874631A1 (de) * 2012-05-15 2015-05-27 Cyclacel Limited Dosierungsschema für sapacitabin und seliciclib
RU2630975C2 (ru) 2012-05-16 2017-09-15 Новартис Аг Режим дозирования pi-3 киназы
WO2014001282A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
EP2907514B1 (de) 2014-02-17 2019-10-23 Manros Therapeutics Purinderivatverbindungen zur medizinischen Verwendung
EP3148532B1 (de) 2014-05-28 2021-03-03 Piramal Enterprises Limited Pharmazeutische kombination, die einen cdk-inhibitor und einen thioredoxin-reduktase-inhibitor enthält, zur behandlung von krebs
AU2016347881A1 (en) 2015-11-02 2018-05-10 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10729692B2 (en) 2017-02-26 2020-08-04 Institute For Cancer Research Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
WO2018187478A1 (en) * 2017-04-04 2018-10-11 University Of Miami Biomarkers indicative of prostate cancer and treatment thereof
TW202038957A (zh) 2018-12-21 2020-11-01 日商第一三共股份有限公司 抗體-藥物結合物與激酶抑制劑之組合
CN112794853B (zh) * 2021-01-12 2021-11-30 江汉大学 一种有机硒化合物及其制备方法与应用
CN112794852B (zh) * 2021-01-12 2021-11-30 江汉大学 一种含硒有机化合物及其制备方法与应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844577A (en) * 1958-07-22 Certificate of correction
US2691654A (en) * 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US2830053A (en) * 1955-03-25 1958-04-08 Burroughs Wellcome Co 6-substituted purine compounds and method of making
US2966488A (en) * 1956-07-30 1960-12-27 Shive William Substituted alkylaminopurines
US3213095A (en) * 1963-04-04 1965-10-19 American Cyanamid Co N-benzylation of adenine
US3930005A (en) * 1973-06-15 1975-12-30 Squibb & Sons Inc Antiinflammatory agents and their use
US3862189A (en) * 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
DE2355536A1 (de) * 1973-11-07 1975-05-22 Merck Patent Gmbh Adeninderivate und verfahren zu ihrer herstellung
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
DE2550000A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Neue purin-derivate und verfahren zu ihrer herstellung
GB1544419A (en) * 1975-11-19 1979-04-19 Science Union & Cie Purines and pyrazolo-pyrimidines a process for their preparation and pharmaceutical compositions containing them
US4189485A (en) * 1977-08-23 1980-02-19 Takeda Chemical Industries, Ltd. Purine derivatives
DE2804416A1 (de) * 1978-02-02 1979-08-09 Boehringer Mannheim Gmbh Neue purin-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
EP0363320A3 (de) * 1988-10-06 1991-11-21 Ciba-Geigy Ag Substituierte 9H-Purine
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
PT874846E (pt) 1995-11-01 2003-08-29 Novartis Ag Derivados de purina e processos para a sua preparacao
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1999007705A1 (en) * 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
WO2003002565A1 (en) * 2001-06-27 2003-01-09 Cyclacel Limited 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders
AU2003279690A1 (en) * 2002-06-27 2004-01-19 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
JP4664205B2 (ja) * 2002-10-15 2011-04-06 アイアールエム エルエルシー 骨形成を誘導する組成物および方法
US7960397B2 (en) * 2007-12-28 2011-06-14 Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions

Also Published As

Publication number Publication date
DK1308447T3 (da) 2011-06-20
ATE234838T1 (de) 2003-04-15
FR2741881B1 (fr) 1999-07-30
DE69638337D1 (de) 2011-04-14
EP1308447B1 (de) 2011-03-02
US20100273802A1 (en) 2010-10-28
PT874847E (pt) 2003-08-29
DK0874847T3 (da) 2003-07-14
JP4340796B2 (ja) 2009-10-07
US20020049218A1 (en) 2002-04-25
US20090030019A1 (en) 2009-01-29
CA2238843A1 (fr) 1997-06-12
FR2741881A1 (fr) 1997-06-06
CA2238843C (fr) 2012-04-10
ES2195027T3 (es) 2003-12-01
US8163762B2 (en) 2012-04-24
JP2000501408A (ja) 2000-02-08
ATE500255T1 (de) 2011-03-15
US20040235868A1 (en) 2004-11-25
US20030186999A1 (en) 2003-10-02
EP0874847A1 (de) 1998-11-04
EP1308447A1 (de) 2003-05-07
WO1997020842A1 (fr) 1997-06-12
US6316456B1 (en) 2001-11-13
EP0874847B1 (de) 2003-03-19
DE69626855T2 (de) 2003-12-24
ES2364722T3 (es) 2011-09-13
PT1308447E (pt) 2011-06-07

Similar Documents

Publication Publication Date Title
ATE234838T1 (de) Purinederivate mit antipoliferativer wirkung und ihre biologischen eigenschaften
CO4480021A1 (es) Derivados de amino(tio)eter
DE60040905D1 (de) VERFAHREN ZUR HERSTELLUNG VON (E)-(6-i2-i4-(4-FLUORPHENYL)-6-ISOPROPYL-2-iMETHYL(METHYLSULFONYL)AMINO PYRIMIDIN-5-YL VINYL (4R,6S)-2,2-DIMETHYLi1,3 DIOXAN-4-YL)ESSIGSÄURE-TERT-BUTYLESTER
ATE415394T1 (de) Zwischeprodukte zur herstellung von retroviralen protease-hemmern
ATE218555T1 (de) Octacylodepsideptide mit endoparasitizider wirkung
DK0657458T3 (da) Inhibitorer af proteinkinase-C
DE59408268D1 (de) Verfahren zur Herstellung von N-(2-Hydroxyethyl)-piperazin
DE69232907D1 (de) Neue heterocyclische/cyclische amine
DE59309819D1 (de) Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten zur Behandlung von Erkrankungen, die durch die nichtenzymatische Glykosylierung bedingt sind
ZA913033B (en) N-(3-fluoro-2-phosphonylmethoxypropyl)derivatives of purine and pyrimidine heterocyclic basis,their preparation and use
PT1362045E (pt) Derivados de imidazole 2-tio substituidos e seu uso na industria farmaceutica
ATA152093A (de) Neue guanidin- und amidinsalze von 7-amino-3-hydroxymethyl-3-cephem-4-carbonsäure
DE69830866D1 (de) Verfahren zur Herstellung von Nitroguanidin-Derivaten ausgehend von 2-Nitroimino-hexahydro-1,3,5-triazinen in Anwesenheit von Ammoniak, primärem oder sekundärem Amin
DE59402263D1 (de) Verfahren zur Herstellung von N-substituierten Pyrrolid-2-onen
FI930367A (fi) Puridinderivat
DE69425405T2 (de) Verbessertes Verfahren zur Herstellung von 2,4-di(alkylamine)-6-alkylthio-s-Triazinen und 2,4-alkylamine-4,6-di(alkylthio)-s-Triazinen
DE69116251D1 (de) Verfahren zur Herstellung von 6-(substituiertes Aminopropionyl)-Derivaten von Forskolin
DE59008523D1 (de) Verfahren zur Herstellung von Sulfonylharnstoff-Salzen und ihre Verwendung als Herbizide.
ATE199556T1 (de) Verfahren zur fraktionierung von deacylierten glycerophospholipiden
DE69331305T2 (de) Zwischenprodukte und Verfahren zur Herstellung von 5,6-Dihydropyrrolo[2,3-d]pyrimidinen
ES2068040T3 (es) Sales de 3-(cis-2,6-dimetilpiperidino)-sidnonimina.
DE59509391D1 (de) Verfahren zur Herstellung von N-(4-Fluor-phenyl)-N-isopropyl-chloracetamid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition